Cannabis and cannabinoids in dermatology: a systematic review and meta-analysis of quantitative outcomes
Pim Sermsaksasithorn 1 2, Tanawin Nopsopon 1 2 3, Chatpol Samuthpongtorn 1 2, Korn Chotirosniramit 1 2, Krit Pongpirul 1 2 4 5 6
- 1Center of Excellence in Preventive and Integrative Medicine and Department of Preventive and Social Medicine, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.
- 2School of Global Health, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.
- 3Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States.
- 4Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.
- 5Department of Infection Biology & Microbiomes, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom.
- 6Clinical Research Center, Bumrungrad International Hospital, Bangkok, Thailand.
Affiliationer
Objective: Cannabinoids, present in Cannabis sativa, modulate the signaling and receptor expression of the endocannabinoid system (ECS), potentially impacting various skin conditions. However, current evaluations of their clinical effectiveness remain largely descriptive. This study aimed to quantitatively assess the effectiveness of cannabinoids, including Cannabis sativa extracts, in treating dermatologic disorders.
Design: Systematic review and meta-analysis.
Data sources: PubMed, Embase, Scopus, Web of Science, and CENTRAL from inception to 30 June 2024.
Eligibility criteria for selecting studies: We included randomized controlled trials and observational studies that evaluated the efficacy or effectiveness of medical cannabis or cannabinoid-based interventions in managing dermatologic conditions, regardless of the comparator type.
Data extraction and synthesis: Two reviewers independently extracted data and assessed risk of bias. Outcomes were categorized into subjective outcomes, objective outcomes, and disease-specific composite scores. Meta-analyses used standard mean differences (SMDs) with 95% confidence intervals (CIs). Study quality was assessed using RoB 2 and ROBINS-I tools.
Results: We included 3,359 participants from eleven randomized controlled trials, three quasi-experimental studies, and three observational studies. Interventions included topical formulations of cannabis extract ointment, cannabidiol, N-acylethanolamine (PEA), alkylamides, and HU-210. A statistically significant reduction in pruritus was observed among participants treated with cannabinoids (SMD = -0.29, 95% CI: -0.52 to -0.06, I2 = 0%). No significant effects were found for skin dryness (SMD = -0.22, 95% CI: -0.58 to 0.14, I2 = 20%), erythema (SMD = -0.33, 95% CI: -0.65 to 0.00, I2 = 0%), or quality of life (SMD = -0.15, 95% CI: -0.64 to 0.34, I2 = 58%). Disease-specific scores for atopic dermatitis (SMD = -0.19, 95% CI: -0.44 to 0.05, I2 = 0%) and transepidermal water loss (SMD = 0.16, 95% CI: -0.60 to 0.93, I2 = 68%) also showed no significant differences.
Conclusion: Cannabinoids produced a modest but statistically significant reduction in pruritus, suggesting clinical relevance for symptom management. However, no significant benefits were observed for other dermatologic outcomes. Larger, standardized randomized trials are needed to clarify their therapeutic potential in dermatology.
